NCT05993975View on ClinicalTrials.gov

Effects of Intrathecal Dexmedetomidine as an Adjuvant to Low Dose Hyperbaric 0.5% Bupivacaine

PHASE4CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

July 20, 2021

Primary Completion Date

February 18, 2022

Study Completion Date

February 18, 2022

Conditions
Post Operative Pain
Interventions
DRUG

Bupivacain 0.5%

Bupivacaine hydrochloride was given without any adjuvant

DRUG

Dexmedetomidine Hydrochloride

Use of Dexmedetomidine Hydrochloride 5 micrograms (1 mL) as an adjuvant with bupivacaine hydrochloride

Trial Locations (1)

74200

Syed Muhammad Abbas, Karachi

All Listed Sponsors
lead

Sindh Institute of Urology and Transplantation

OTHER

NCT05993975 - Effects of Intrathecal Dexmedetomidine as an Adjuvant to Low Dose Hyperbaric 0.5% Bupivacaine | Biotech Hunter | Biotech Hunter